BioVersys to Showcase Pipeline Data at ESCMID Global 2026
Event summary
- BioVersys will present data on BV100 (CRABC) and BV500 (NTM) at ESCMID Global 2026, April 17-21.
- BV100 Phase 3 trial (RIV-TARGET) targets carbapenem-resistant Acinetobacter baumannii infections.
- BV500 program has a global research collaboration with Shionogi & Co., Ltd.
- CEO Marc Gitzinger to discuss funding and policy priorities shaping infectious disease research.
The big picture
BioVersys' participation in ESCMID Global 2026 underscores the critical need for novel antibiotics amid rising antimicrobial resistance. The company's focus on CRABC and NTM infections aligns with global health priorities, particularly as COVID-19 has exacerbated the spread of drug-resistant pathogens. The strategic partnerships with Shionogi and other institutions highlight the importance of cross-industry collaboration in addressing these unmet medical needs.
What we're watching
- Clinical Progress
- The pace at which BV100 advances through Phase 3 trials and regulatory approvals.
- Partnership Dynamics
- Whether BioVersys can leverage its collaboration with Shionogi to accelerate BV500 development.
- Market Demand
- How the increasing incidence of carbapenem-resistant infections will impact BV100's commercial potential.
Related topics